跳至主要内容
临床试验/NCT03144882
NCT03144882已完成不适用

Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 71 人开始时间: 2015年2月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
71
主要终点
Mean Interlukin-6 Levels

研究概览

简要总结

Programmed ingestion of turmeric has no adverse effects and reduces plasma level of hs-CRP, IL-6 and TNF-α accompanying with increases albumin levels in hemodialysis patients. Turmeric can be considered as an effective anti-inflammatory supplement in hemodialysis patients.

详细描述

Hemodialysis patients over 18 years were recruited after fulfilling the inclusion criteria.Seventy-one hemodialysis patients were randomized into two groups: the trial group (n =35 ) and the controls (n =36 ); a randomization numeric table was used for allocation sequence . Trial group received turmeric and control group received placebo for 12 weeks. Biochemical determinations included levels of serum albumin (Alb), potassium (K) ,blood urea nitrogen (BUN), serum creatinine (Cr), IL-6 level, TNF- α , and liver function tests and hs-CRP at the start and end of the study were measured.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females undergoing maintenance hemodyalisis,
  • Age ≥18 year
  • Clinically stable and receiving adequate hemodialysis defined by a single pool Kt/V≥1.20 or no less than 3 dialysis sessions per week with a total dialysis time ≥12 hour per week for at least 3 month before enrollment,
  • Diabetic patients must be willing to commence insulin therapy if deemed necessary for plasma glucose control.

排除标准

  • Active malignant disease (defined as less than 5 year since receiving a diagnosis of being malignancy-free)
  • Critical illness as defined by the need for respiratory or circulatory support (in an intensive care unit)
  • Active vasculitis
  • Severe congestive heart failure (New York Heart Association class IV)
  • Severe chronic systemic infectious or inflammatory disease
  • Liver disease (defined as serum alanine aminotransferase or aspartate aminotransferase levels greater than three times the upper limit of normal)
  • Known or suspected allergy to trial product(s) or related products
  • Treatment with immunosuppressive agents or receipt of any investigational drug within one month preceding screening
  • Recent or current use of anti-inflammatory corticosteroids agents
  • A scheduled renal transplantation within the trial period

研究组 & 干预措施

intervention

Active Comparator

the trial group (n =35 )

干预措施: Curcumin Pill (Drug)

placebo

Placebo Comparator

control group

干预措施: Placebo (Drug)

结局指标

主要结局

Mean Interlukin-6 Levels

时间窗: one year

blood even

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

nooshin dalili

Assistant Professor of SBMU

Shahid Beheshti University of Medical Sciences

相似试验